MorningSignal
Research Platform
2026-07-23 07:34
type: earnings-brief session: AM date: 2026-07-21 status: provisional-release-only daily_note: "[[Daily/2026-07-21]]" tags: - sellside - earnings
← [[Daily/2026-07-21|Back to the daily note]]
Evidence cutoff: 2026-07-21, 08:09 ET. Premarket quotes are indicative public prints, not official consolidated prices.
Universe: 21 qualifying BMO releases plus 10 prior-evening AMC catch-ups, all US-listed and above $2 billion in the deterministic collection set.
Method: Public unauthenticated sources and deterministic local tools only. No API key, model API, or token-backed source was read or used.
The tape is applying a much higher hurdle than sell-side EPS consensus. [[Danaher|DHR]], [[MSCI]], and [[Equifax|EFX]] all met or beat published point estimates and maintained or raised some guidance, yet fell roughly 11%–12% premarket because the market cared more about bioprocessing conversion, net-new subscription sales, and Workforce Solutions margins than headline EPS. [[Northrop Grumman|NOC]] also beat EPS, but the entire beat was more than explained by an unusually low tax rate while segment profit and margins fell. Those four are the clearest examples of negative stock delta despite non-negative estimate delta.
The cleanest positive operating revisions were [[3M|MMM]], [[General Motors|GM]], [[Novartis|NVS]], and [[Valmont Industries|VMI]]. 3M combined 5.4% adjusted organic growth, margin expansion, and a meaningful full-year EPS raise. GM raised EBIT, EPS, and free-cash-flow guidance after North America margin and cash conversion improved. Novartis beat core EPS and core operating income on rapid growth from priority brands, but Entresto generic erosion and a slightly lower core margin keep the FY2 debate alive. Valmont raised sales and EPS guidance on strong North American infrastructure demand.
The quality gate materially changes several headlines. [[Vicor|VICR]] reported $1.04 EPS versus a $0.62 public point, but an approximately $10.9 million tax benefit explains most of the apparent beat. [[United Community Banks|UCB]] reported $0.95 GAAP EPS, yet adjusted operating EPS was only $0.71 versus a $0.80 point and the quarter included a $38.5 million provision release. [[Atlantic Union Bankshares|AUB]] also benefited from a business-sale gain. [[Halliburton|HAL]] had non-recurring credits in GAAP EPS; its clean $0.55 adjusted EPS was essentially in line.
Every current BMO company is PROVISIONAL — RELEASE ONLY because no complete transcript or attributable full Q&A was available by the cutoff. Conviction is capped and all 21 are queued for the PM catch-up. The prior-evening AMC views remain provisional where calls occur today: [[Crown Holdings|CCK]] retains the prior PM BUY up to $118, while [[Steel Dynamics|STLD]], [[AGNC Investment|AGNC]], [[Calix|CALX]], and the remaining call-pending names require the scheduled Q&A before any higher-conviction change.
| Company | Evidence state | Business delta | Estimate delta | Stock delta at 08:09 ET | Action | Conviction |
|---|---|---|---|---|---|---|
| [[3M | MMM]] | Release only | Positive | Positive | +6.2% | HOLD; add only on sustained organic/margin proof |
| [[General Motors | GM]] | Release only | Positive | Positive | +1.0% | HOLD |
| [[Novartis | NVS]] | Release only | Positive | Slightly positive | +2.8% | HOLD |
| [[Valmont Industries | VMI]] | Release only | Positive | Positive | +3.3% | HOLD |
| [[Danaher | DHR]] | Release only | Mixed | Slightly positive | -12.2% | WAIT near $170 or for bioprocessing conversion |
| [[MSCI]] | Release only | Mixed-negative | Flat | -10.9% | WAIT near $525 or for net-sales acceleration | Medium |
| [[Equifax | EFX]] | Release only | Mixed | Slightly positive | -10.7% | WAIT near $155 or for Workforce margin proof |
| [[Northrop Grumman | NOC]] | Release only | Negative | Low-quality positive | -3.0% | WAIT near $485 or for segment-margin recovery |
| [[United Community Banks | UCB]] | Release only | Negative | Negative on adjusted basis | -2.9% | WAIT; require core EPS above $0.80 and deposit growth |
| [[Vicor | VICR]] | Release only | Positive | Low-quality positive | +2.5% | WAIT near $210 or for capacity/cash proof |
| [[Crown Holdings | CCK]] | Prior release; call today | Positive | Positive | +2.6% | Retain BUY up to $118; call-provisional |
| [[Calix | CALX]] | Prior release; call today | Mixed | Negative | -14.2% | WAIT at $30 or for gross margin at least 53% |
The deterministic AM collector generated /Users/max/morningsignal-research/state/earnings/earnings_context_2026-07-21_AM.json at 08:02:50 ET and returned 21 qualifying companies, 21 current-result evidence records, and zero conference-call evidence records. The point estimates below came from the dated public Nasdaq/Kiplinger calendar or a clearly identified public FactSet/news reference. A public consensus range and a verified buy-side hurdle were not available for any of the 21 names; none is inferred. No covered ticker had a live threshold in the TIF Analytical Ledger. Where a precise valuation-implied earnings bar could not be derived from current FY1/FY2 consensus data, the report uses an explicit price or operating confirmation level rather than fabricating a multiple.
| Company | Prior company guide / operating bar | Dated Street EPS point | Result | Public range / verified hurdle / TIF threshold |
|---|---|---|---|---|
| [[Novartis | NVS]] | FY sales low-single-digit growth; core operating income down low single digits | $2.20 | $2.41 core |
| [[Charles Schwab | SCHW]] | No numeric quarterly guide; bar was core net-new assets above $100B and durable NII | $1.56 FactSet | $1.62 adjusted |
| [[Danaher | DHR]] | FY core growth 3%–4%; adjusted EPS $8.35–$8.55 | $1.84 | $1.94 adjusted |
| [[Marsh McLennan | MRSH]] | No numeric guide; bar was at least 5% underlying growth and margin stability | $2.88 | $2.96 adjusted |
| [[3M | MMM]] | FY adjusted EPS $8.50–$8.70 | $2.27 | $2.40 adjusted |
| [[Northrop Grumman | NOC]] | FY sales $43.5B–$44.0B; MTM EPS about $27.40–$27.90 | $6.84 | $7.68 |
| [[General Motors | GM]] | FY EBIT-adjusted $13.5B–$15.5B; adjusted EPS $11.50–$13.50 | $3.18 | $3.57 adjusted |
| [[MSCI]] | FY FCF $1.47B–$1.53B; operating expense $1.49B–$1.53B | $4.89 | $4.94 adjusted | Not public / not verified / none |
| [[D.R. Horton | DHI]] | No current numeric quarterly EPS guide in evidence | $2.99 | $3.20 |
| [[Halliburton | HAL]] | No numeric guide; bar was international growth and stable clean margin | $0.54 | $0.55 adjusted |
| [[KeyCorp | KEY]] | No numeric guide; bar was NIM expansion without credit slippage | $0.42 | $0.44 |
| [[Synchrony Financial | SYF]] | No numeric guide; bar was purchase growth plus improving loss rates | $2.08 | $2.59 |
| [[Equifax | EFX]] | Q2 revenue $1.68B–$1.71B; adjusted EPS $2.15–$2.25 | $2.21 | $2.25 adjusted |
| [[Genuine Parts | GPC]] | FY adjusted EPS $7.50–$8.00 | $2.10 | $2.15 adjusted |
| [[Ally Financial | ALLY]] | No numeric guide; bar was NIM/credit improvement | $1.25 | $1.21 adjusted |
| [[Hasbro | HAS]] | FY constant-currency revenue growth 3%–5%; margin 24%–25% | $1.16 | $1.28 adjusted |
| [[Vicor | VICR]] | No numeric guide; bar was backlog conversion and gross-margin recovery | $0.62 | $1.04 GAAP |
| [[Valmont Industries | VMI]] | FY sales $4.2B–$4.4B; EPS $21.50–$23.50 | $5.76 | $6.14 |
| [[Atlantic Union Bankshares | AUB]] | No numeric guide; bar was core NIM and deposit-funded growth | $0.92 | $0.94 adjusted |
| [[United Community Banks | UCB]] | No numeric guide; bar was adjusted operating EPS at least $0.80 | $0.80 | $0.71 adjusted operating |
| [[OFG Bancorp | OFG]] | No verified current guide | $1.18 | EPS blocked; revenue $174.8M |
Variance and quality. Net sales were $14.408 billion, up 3% reported and 1% constant currency. Core EPS of $2.41 beat the $2.20 point by 9.5%; core operating income of $5.94 billion was above the roughly $5.31 billion Visible Alpha point. Core margin was 41.2%, down about 70 basis points constant currency, and free cash flow fell 12% to $5.6 billion, so this is a strong franchise beat rather than flawless conversion. Kisqali grew 43% constant currency, Kesimpta 32%, Scemblix 89%, Pluvicto 43%, and Leqvio 59%; Entresto fell 51% as generics arrived. FY sales and core-operating-income guidance was reaffirmed.
Call questions and bridge. Quantify the H2 Entresto erosion curve, the capacity ceiling for radioligand therapies, and the probability-weighted readout/calendar for the next pipeline catalysts. FY1 core EPS moves slightly higher on the Q2 beat; FY2 depends on priority-brand growth staying above 20%, radioligand capacity, and pipeline launches offsetting the patent cliff. Old narrative: a concentrated patent cliff overwhelms new launches. New narrative: the new-product engine is currently outrunning erosion, but margin and cash conversion show the replacement is not free. Pillars: demand strengthened, margin slightly weakened, pipeline timing unchanged, cash conversion weakened. Premarket +2.8% to about $153.77 confirms a positive but not euphoric stock delta. HOLD, medium conviction; add only below $145 or after priority-brand growth remains above 20% with core margin at least 41%. Falsification: core margin below 40% or priority-brand growth below 15%.
Variance and quality. Adjusted EPS of $1.62 beat the $1.56 FactSet point by 3.8%; revenue of $7.1 billion beat roughly $6.9 billion and grew 21%. Core net-new assets were $120 billion versus $74 billion a year ago, client assets reached $13.08 trillion, accounts 48 million, and average daily trades rose 57% to 11.9 million. Bank loans grew 33% to $67 billion. This is a high-quality volume beat, but the release evidence did not provide enough detail to verify whether client-cash sorting, deposit beta, or supplemental borrowing improved enough for a durable NII revision.
Call questions and bridge. Demand a bridge from $120 billion of core inflows to cash balances, deposit costs, NII, and bank-loan growth; quantify the share of trading growth that is cyclical versus retained engagement; and ask how AI/zero-price service competition affects service cost and advice pricing. FY1 rises modestly on revenue and activity; FY2 needs the asset inflows to monetize without renewed cash sorting. Old narrative: Schwab is a rate-sensitive broker recovering from a funding shock. New narrative: it is again an organic asset-gathering machine, but the market wants conversion, not only flows. Pillars: organic growth strengthened, engagement strengthened, funding economics unresolved, competitive risk unchanged. Premarket -1.5% to about $101 implies the public beat did not clear the embedded bar. HOLD, medium conviction; require quarterly core NNA above $100 billion and stable-to-higher NII. Falsification: core NNA below $75 billion or renewed deposit contraction.
Variance and quality. Revenue was $6.265 billion, up 5.5%; core growth was 3% and 4.5% excluding respiratory. Adjusted EPS was $1.94 versus $1.84, a 5.4% beat. Free cash flow rose 15.5% to $1.265 billion. The problem is bioprocessing: customer project timing constrained reported revenue even as orders grew mid-teens. Q3 core growth is only 2%–3%. FY core growth remains 3%–4%, while adjusted EPS guidance rose to $8.45–$8.60 from $8.35–$8.55.
Call questions and bridge. Quantify delayed bioprocessing projects by geography and quarter, book-to-bill and cancellation risk, and the margin cost of carrying capacity ahead of conversion. FY1 EPS moves up about 1%; FY2 can move materially higher only if mid-teens orders become revenue without discounting or inventory digestion. Old narrative: bioprocessing normalization produces clean incremental margins. New narrative: demand signals have normalized before revenue, creating a duration gap the market refuses to capitalize. Pillars: orders strengthened, reported demand mixed, cash conversion strengthened, timing/credibility weakened. Premarket -12.2% to $176.50 is a severe negative stock delta and identifies the buy-side hurdle as near-term conversion, not EPS. WAIT near $170 or until bioprocess core growth exceeds 5%. Falsification: orders slow below high-single digits or FY core growth falls below 3%.
Variance and quality. Revenue of $7.404 billion grew 6% reported and 5% underlying. Adjusted EPS was $2.96 versus $2.88, a 2.8% beat; adjusted operating income grew 5%, roughly in line with underlying revenue. This is a clean, modest beat without evidence of large margin leverage. The release did not provide a numeric full-year guide.
Call questions and bridge. Ask for organic growth by pricing versus exposure and new business, renewal-rate deceleration across commercial insurance, and the integration/cost synergy path for acquisitions. FY1 edges higher 1%–2%; FY2 remains a mid-single-digit organic plus capital deployment algorithm unless pricing softens faster. Old narrative: pricing and intellectual-capital scale sustain high-single-digit EPS compounding. New narrative: the compounding engine is intact but the quarter did not reset the growth rate. Pillars: demand unchanged-positive, pricing unresolved, margin unchanged, capital allocation unchanged. Premarket +2.4% to $186.45 is a positive stock delta. HOLD, medium conviction; confirmation requires at least 5% underlying growth and operating-income growth at least matching revenue. Falsification: underlying growth below 3% or material margin contraction.
Variance and quality. Sales were $6.5 billion, up 2.4% reported; adjusted organic sales grew 5.4%. Adjusted operating margin expanded 40 basis points to 24.9%, and adjusted EPS of $2.40 beat $2.27 by 5.7% and rose 11%. Free cash flow was $1.348 billion. GAAP EPS of $1.78 contains large, opposing Solventum, divestiture, PFAS/litigation, and transformation adjustments; the adjusted operating beat is nevertheless supported by organic growth and margin. FY adjusted EPS rose to $8.80–$8.95 from $8.50–$8.70; FCF is guided to $4.7B–$4.9B.
Call questions and bridge. Require the organic-growth split between volume, price, and channel inventory; the recurring transformation savings embedded in margin; and an updated cash map for PFAS/earplug liabilities. The guide midpoint rose about 3.2%, making FY1 a true upward revision. FY2 depends on maintaining organic growth above 3% and margin near 25% after restructuring benefits normalize. Old narrative: legal liabilities and portfolio surgery obscure a mature low-growth industrial. New narrative: execution is producing real organic and margin leverage, though legal cash calls remain the valuation ceiling. Pillars: demand strengthened, margin strengthened, cash conversion strengthened, legal risk unchanged. Premarket +6.2% to $169 is confirmatory. HOLD, medium conviction; confirmation requires organic growth above 4% and adjusted margin above 24.5%. Falsification: organic growth below 2% or FCF guide below $4.5 billion.
Variance and quality. Sales were $10.876 billion, slightly above the $10.81 billion point and up 5%. EPS was $7.68 versus $6.84, but the effective tax rate fell to 6.3% from 17.7%; the approximate $133 million benefit is about $0.93 per share, more than the entire $0.84 beat. Segment operating income fell 5% and margin fell to 10.6% from 11.8%. Defense Systems margin dropped to 7.5% from 12.7% and Space to 8.6% from 10.6%; backlog rose 9% to $104.7 billion and awards were $20 billion. Sales guidance rose $250 million to $43.75B–$44.25B, and MTM EPS rose $1.20 to $28.60–$29.10; FCF stayed $3.1B–$3.5B.
Call questions and bridge. Reconcile the Defense and Space margin compression by program, quantify remaining loss provisions and cash milestones, and separate the tax benefit from repeatable EPS. FY1 reported EPS rises because of tax, while operating EPS is flat-to-down; FY2 requires program-margin recovery and backlog cash conversion. Old narrative: record defense demand supports visible profitable growth. New narrative: demand visibility strengthened while execution quality deteriorated. Pillars: backlog strengthened, segment margin weakened, cash guide unchanged, EPS quality weak. Premarket -3.0% to $508 reflects that distinction. WAIT near $485 or until segment margin returns above 11.5%. Falsification: another charge or FCF below $3.1 billion.
Variance and quality. Revenue was $48.026 billion versus roughly $47.1 billion and up about 2%. Adjusted EPS was $3.57 versus $3.18, a 12% beat; EBIT-adjusted was $3.9 billion. GM North America adjusted margin reached 8.6% versus 6.1%, and adjusted automotive free cash flow rose 78% to $5.033 billion. GAAP net income fell 31% to $1.305 billion because of special items, so adjusted-to-GAAP reconciliation matters, but cash supports the operating beat. FY EBIT-adjusted guidance rose to $14B–$16B, adjusted EPS to $12–$14, and FCF to $9.5B–$11.5B.
Call questions and bridge. Ask for tariff cost and mitigation by quarter, incentive/ATP versus volume in North America, EV loss and capacity cadence, and pension/working-capital contributions to FCF. FY1 midpoint rises about 3.5% for EBIT and 4% for EPS; FY2 requires price discipline and lower EV drag rather than another working-capital tailwind. Old narrative: tariffs, incentives, and EV losses overwhelm buybacks. New narrative: North American margin and cash are offsetting those pressures for now. Pillars: price/mix strengthened, margin strengthened, cash strengthened, policy/EV risk unchanged. Premarket +1.0% to $76.59 is positive but muted. HOLD, medium conviction; confirm GMNA margin above 8% and FCF above $10 billion. Falsification: GMNA margin below 7% or guide reversal.
Variance and quality. Revenue was $867 million versus roughly $868.8 million, while adjusted EPS of $4.94 was just above $4.89. Adjusted EBITDA margin improved to 62.1%. Recurring subscription revenue grew 9% to $613.4 million and Index retention was 97.5%, but total net new sales fell 1.4%; Analytics net sales fell 31.1% and Sustainability & Climate fell 34.9%. FY FCF rose only to $1.485B–$1.545B, while operating-expense guidance increased to $1.535B–$1.575B.
Call questions and bridge. Quantify gross sales, churn, and implementation delays in Analytics and Sustainability; separate ETF AUM market beta from fee-rate/flow growth; and explain why higher expense is not producing net-sales acceleration. FY1 EPS is broadly unchanged because margin offsets the revenue miss. FY2 moves lower if weak net sales persist because today’s bookings become tomorrow’s recurring revenue. Old narrative: index-linked beta plus cross-sell sustains double-digit compounding. New narrative: the installed base is resilient, but the incremental sales engine has stalled outside Index. Pillars: retention strong, new business weakened materially, margin strengthened, reinvestment efficiency weakened. Premarket -10.9% to $557 is a negative stock and duration delta. WAIT near $525 or until total net sales grow above 10%. Falsification: another negative net-sales quarter or retention below 96%.
Variance and quality. Fiscal Q3 EPS was $3.20 versus $2.99, a 7% beat, while revenue of $9.2 billion was approximately in line. Homebuilding revenue grew 1% to $8.7 billion; closings rose 4% to 23,983 and net orders were 23,084 units/$8.4 billion. Net income fell 12% and EPS fell 5% year over year. Home gross margin was 20.7%, with elevated incentives expected in Q4. Operating cash flow was $880.8 million year to date; debt/capital was 23% and repurchases were $615.7 million.
Call questions and bridge. Demand the Q4 incentive and gross-margin bridge, cancellation/order pace by price point, and land-spend versus repurchase priorities. FY1 moves modestly higher on EPS, but FY2 depends on rate-sensitive demand and whether incentives stabilize rather than deepen. Old narrative: scale and entry-level positioning defend turns. New narrative: scale is protecting volume, but affordability pressure is being paid through margin. Pillars: volume strengthened, pricing/margin weakened, balance sheet strong, demand visibility mixed. Premarket +0.9% to $146.08 is a modest confirmation. HOLD, medium conviction; require gross margin above 20.5% and orders at least flat. Falsification: margin below 19.5% or orders down more than 10%.
Variance and quality. Revenue was $5.714 billion versus $5.65 billion, up 5.8% year over year and 3.7% sequentially. Adjusted EPS of $0.55 was essentially in line with $0.54 and flat sequentially/year over year; adjusted operating margin was 12%. GAAP EPS of $0.64 included approximately $95 million of pretax credits. Free cash flow was $668 million and buybacks about $200 million. The sales beat is real; the EPS headline is not an inflection.
Call questions and bridge. Quantify international versus North American growth and decrementals, pricing versus utilization, and whether the free-cash-flow jump includes working-capital timing. FY1 is unchanged to slightly higher on revenue, FY2 needs international incremental margins and stabilization in North America. Old narrative: international strength offsets North American softness. New narrative: that mix is working on revenue but has not yet created per-share growth. Pillars: demand strengthened, margin unchanged, cash strengthened, EPS quality mixed. Premarket -3.8% to $33.78 is a negative stock delta. WAIT below $31 or until adjusted EPS grows and margin exceeds 13%. Falsification: international growth below mid-single digits or FCF conversion below 70%.
Variance and quality. EPS was $0.44 versus $0.42; revenue of $1.964 billion was roughly in line with $1.97 billion. NII rose 9% year over year and 2% sequentially; NIM increased two basis points to 2.89%. Loans grew 2.2% sequentially and deposits 0.2%. Net charge-offs rose to 42 basis points from 38 and NPLs to 0.73% from 0.62%; allowance/loans slipped four basis points to 1.56%. CET1 was 11.2% and buybacks were $341 million.
Call questions and bridge. Identify the credit deterioration by portfolio/vintage, explain reserve coverage versus criticized loans, and bridge Q3 NIM through deposit beta and securities repricing. FY1 rises slightly on NII but credit cost absorbs part of the beat; FY2 requires NIM expansion without normalization above roughly 50-basis-point charge-offs. Old narrative: liability repricing drives a clean earnings recovery. New narrative: NII is recovering, but credit is starting to claim the benefit. Pillars: NIM strengthened, loan growth strengthened, funding mixed, credit weakened. Premarket -1.0% to $23.09 is consistent. HOLD, medium conviction; confirm NIM above 2.90% and NCO below 45 basis points. Falsification: NPL above 0.9% or allowance below 1.5% as losses rise.
Variance and quality. EPS of $2.59 beat $2.08 by 24.5%, but the $163 million reserve release—versus $265 million a year ago—contributed roughly $0.37 per share after tax. Purchase volume grew 8% to $49.8 billion; loans rose 2%, accounts were flat, NIM improved 30 basis points to 15.08%, and NII grew 2% to $4.6 billion. Delinquencies improved to 4.16% from 4.18% and net charge-offs to 5.43% from 5.70%. The allowance remained high at 10.09% of loans.
Call questions and bridge. Ask for reserve-release cadence versus loan growth, loss-rate normalization by vintage, and whether purchase growth is volume or inflation/mix. FY1 rises, but less than the raw EPS beat after normalizing reserve releases; FY2 improves if loss rates stay below 5.75% and purchase growth remains mid-single digits. Old narrative: consumer credit normalization overwhelms strong yields. New narrative: purchase growth, margin, and losses are improving together, although releases flatter EPS. Pillars: demand strengthened, NIM strengthened, credit strengthened, earnings quality mixed. Premarket -0.6% to $72.98 shows a high hurdle. HOLD, medium conviction; confirm NCO below 5.75% and delinquencies below 4.3%. Falsification: NCO above 6% or reserve build resumes without loan acceleration.
Variance and quality. Revenue was $1.700 billion, in the $1.68B–$1.71B guide and roughly at Street. Adjusted EPS of $2.25 was at the top of guide and 1.8% above $2.21. Adjusted EBITDA margin was flat at 32.5%. Workforce Solutions revenue grew 7% to $705.4 million, but its margin fell to 52.1% from 53.3%. FY revenue is $6.71B–$6.78B and adjusted EPS $8.39–$8.69. The company doubled its AI cost-reduction target to $150 million and acquired Círculo; cash return was $366 million.
Call questions and bridge. Quantify Workforce volume/price and the source of 120 basis points of margin compression; separate AI savings from underlying cost inflation; and give acquisition dilution/accretion and integration costs. FY1 is modestly positive at best; FY2 needs Workforce margin recovery and actual savings rather than a larger target. Old narrative: mortgage recovery plus cloud/AI savings restores double-digit EPS growth. New narrative: revenue is on plan, but the highest-quality franchise is not converting and the market distrusts target-based savings. Pillars: demand mixed-positive, Workforce margin weakened, cost program strengthened but unproven, capital allocation mixed. Premarket -10.7% to $160.80 is a clear negative stock delta. WAIT near $155 or until Workforce margin returns above 53%. Falsification: FY revenue below $6.71 billion or Workforce margin below 51%.
Variance and quality. Revenue was $6.537 billion versus $6.43 billion, up 6%. Adjusted EPS was $2.15 versus $2.10 and up 2.4%; GAAP EPS fell to $1.65 from $1.83. Comparable sales grew 3.4%, led by 6.1% in Industrial. FY adjusted EPS stayed $7.50–$8.00, but North American auto sales growth was trimmed to 2.5%–4.5% from 3%–5% and GAAP EPS guidance fell to $5.90–$6.40. FCF remains $550M–$700M.
Call questions and bridge. Ask for auto transaction/count versus price, industrial backlog/order cadence, restructuring/acquisition charges behind GAAP-adjusted divergence, and FCF working capital. FY1 adjusted EPS is unchanged; FY2 depends on industrial strength offsetting softer auto demand and better cash conversion. Old narrative: defensive aftermarket demand plus industrial recovery. New narrative: industrial is carrying a softer auto outlook, leaving the earnings algorithm intact but unimproved. Pillars: industrial demand strengthened, auto demand weakened, adjusted earnings unchanged, GAAP quality weakened. Premarket +1.2% to $123.91 is modestly positive. HOLD, medium conviction; require comp sales above 3% and FCF above $600 million. Falsification: auto growth below 2% or another guide cut.
Variance and quality. Adjusted EPS was $1.21 versus $1.25, while adjusted revenue of $2.276 billion exceeded roughly $2.22 billion. Core pretax income rose 26%; NIM excluding OID improved 18 basis points to 3.63%. Auto originations were $13.3 billion at a 9.09% yield, with 47% top-tier. Auto net charge-offs improved 18 basis points to 1.57% and delinquencies eight basis points to 4.80%, but provision rose $46 million to $430 million on CECL growth. Retail deposits fell $2.6 billion sequentially to $143.6 billion; deposit yield fell 15 basis points.
Call questions and bridge. Explain deposit outflow versus intentional pricing, CECL provision sensitivity to loan growth, used-vehicle/residual assumptions, and the origination risk mix. FY1 is broadly unchanged: better NIM/credit offsets provision. FY2 improves if growth remains top-tier and deposits stabilize. Old narrative: credit losses swamp margin repair. New narrative: credit and margin are repairing, but growth consumes provision and deposits declined. Pillars: NIM strengthened, credit strengthened, originations strengthened, funding weakened. Premarket +0.7% to $45.82 is a constructive read-through despite EPS miss. HOLD, medium conviction; confirm NIM above 3.6%, NCO below 1.75%, and stable deposits. Falsification: deposits fall another 2% or NCO exceeds 2%.
Variance and quality. Revenue was $1.140 billion versus roughly $1.07 billion, up 16%; adjusted EPS of $1.28 beat $1.16. Adjusted operating margin was 24.8% versus 25.2%, so the top-line beat did not expand total margin. Wizards revenue rose 27% to $663.8 million and Magic grew 32% to above $500 million. Consumer revenue grew 5% but posted an $8 million adjusted operating loss; a cyber incident cost about $25 million of revenue and $11 million of expense. Entertainment fell 20%. FY constant-currency revenue growth rose to 5%–7% from 3%–5%, margin to 25%–26%, and a $1 billion buyback was authorized.
Call questions and bridge. Quantify Magic set cadence versus recurring player growth, Consumer breakeven timing, cyber recovery, and buyback timing versus leverage. FY1 moves materially higher; FY2 depends on avoiding Magic content concentration and restoring Consumer profitability. Old narrative: Magic funds a structurally weak toy portfolio. New narrative: Magic is accelerating enough to raise the group guide, but concentration and Consumer losses deepen. Pillars: digital demand strengthened, Consumer economics unchanged-weak, group margin mixed, capital return strengthened. Premarket +1.5% to $82.84 is positive. HOLD, medium conviction; require Consumer breakeven and group margin at least 25%. Falsification: Magic growth below 10% or Consumer loss persists through year-end.
Variance and quality. Revenue was $143.35 million versus roughly $138.4 million, up 26.9% sequentially. Product revenue grew 31.8% year over year and royalty revenue 194%. Gross margin rose to 58.0% from 55.2% sequentially; backlog reached $380 million, up 26% sequentially and 145% year over year. GAAP EPS was $1.04 versus $0.62, but a $10.9 million tax benefit appears to explain roughly $0.39 per share and more than 90% of the apparent beat. The operational inflection is real; the per-share magnitude is not repeatable.
Call questions and bridge. Demand backlog conversion timing/cancellation terms, data-center customer concentration, second-fab capex and utilization, and normalized tax. FY1 operating estimates rise on backlog and margin; FY2 has upside only if new capacity converts without a demand air pocket. Old narrative: differentiated power modules lack scalable capacity and predictable conversion. New narrative: orders/backlog have inflected, but capacity execution and concentrated AI demand now carry the thesis. Pillars: demand strengthened materially, margin strengthened, capacity risk increased, EPS quality weak. Premarket +2.5% to $236.80 is positive but restrained. WAIT near $210 or until two quarters of backlog conversion and positive FCF. Falsification: backlog falls below $300 million or gross margin below 55%.
Variance and quality. Sales were $1.119 billion versus roughly $1.09 billion, up 6.5%. EPS was $6.14 versus $5.76 and up 25.8% from prior adjusted EPS; adjusted operating margin expanded to 14.8% from 13.5%. Infrastructure sales rose 14.8%, with North American utility up 33.9% and Infrastructure margin 17.6%. Agriculture fell 15.8% and International agriculture 28.9% on Middle East weakness. FY sales rose to $4.3B–$4.45B from $4.2B–$4.4B; EPS rose to $22.25–$23.50 from $21.50–$23.50.
Call questions and bridge. Ask for utility backlog/conversion and price-cost, the duration of Middle East weakness, and capital allocation between capacity and buybacks. FY1 midpoint rises roughly 1.7%; FY2 depends on utility/grid demand remaining durable and Agriculture stabilizing. Old narrative: grid infrastructure offsets an agricultural downcycle. New narrative: North American utility is strong enough to raise the whole-company algorithm despite deeper international ag weakness. Pillars: infrastructure demand strengthened, margin strengthened, agriculture weakened, guide credibility improved. Premarket +3.3% to $543 confirms. HOLD, medium conviction; require Infrastructure growth above 10% and margin above 16%. Falsification: utility growth below 5% or group margin below 13.5%.
Variance and quality. GAAP EPS was $1.11 and adjusted EPS $0.94 versus $0.92. A $32.3 million gain on the Bearing sale boosts GAAP, so adjusted EPS is the proper baseline. NII rose 12.7% sequentially to $325.1 million and NIM improved nine basis points to 3.89%, but acquisition accretion income rose to $39.9 million from $32.9 million. Loans grew 2.6% sequentially; deposits only 0.25%, while borrowings rose $576 million. NPAs rose to 0.39% from 0.36%; adjusted efficiency was 47.47%.
Call questions and bridge. Normalize NIM excluding accretion, explain deposit retention/pricing and new borrowing, and bridge acquired credit marks to future provision. FY1 rises slightly on NII; FY2 depends on replacing accretion with organic funding and cost synergies. Old narrative: acquisition scale produces NIM and efficiency gains. New narrative: accretion is arriving, but loans are outrunning deposits and obscuring organic economics. Pillars: reported NIM strengthened, organic funding weakened, efficiency strengthened, credit slightly weakened. Premarket -1.1% to $41.58 is cautious. HOLD, low-medium conviction; require core NIM above 3.7%, deposits matching loans, and NPAs below 0.5%. Falsification: borrowings rise again or NPAs exceed 0.6%.
Variance and quality. GAAP EPS was $0.95, but adjusted operating EPS was $0.71 versus the $0.80 point. The quarter included a $38.5 million pretax provision release tied to Navitas held-for-sale. Revenue grew 7% to $279.3 million; loans grew $332 million, a 6.8% annualized pace, and NIM rose three basis points to 3.68%. Customer deposits fell $295 million sequentially. Core provision was $8.7 million, net charge-offs 0.16%, efficiency 56.7%, and NPAs increased $23 million year over year.
Call questions and bridge. Reconcile GAAP to adjusted EPS and isolate every held-for-sale item; explain customer-deposit loss and replacement cost; quantify Navitas closing/timing and residual exposure; and detail the NPA increase. FY1 operating EPS moves lower relative to the public point; FY2 can recover only if deposit-funded loan growth and clean credit offset lost Navitas income. Old narrative: diversified Southeast growth plus a clean divestiture simplifies the bank. New narrative: reported EPS is flattered, core earnings missed, and funding/asset-quality evidence weakened. Pillars: NIM strengthened, core earnings weakened, deposits weakened, credit weakened modestly. Premarket -2.9% to $35 confirms the negative quality read. WAIT until adjusted operating EPS exceeds $0.80 and deposits grow. Falsification: NPAs rise again or core provision exceeds normalized PPNR growth.
The deterministic evidence contained current revenue of $174.8 million and net income of $53.9 million, but the official investor-relations release was blocked by its web protection and the collector’s public fundamentals call returned HTTP 404. The $1.18 Nasdaq EPS point therefore cannot be compared with a verified current EPS. No guide, consensus range, verified hurdle, valuation-implied bar, or call evidence could be validated. Premarket was indicated near $50, unchanged, but that print cannot substitute for results. PROVISIONAL — SOURCE BLOCKED; WAIT, low conviction. The PM task must retrieve the official release or SEC exhibit, normalize EPS, and answer NIM/deposit/credit/capital questions before any action. Confirmation requires verified adjusted EPS above $1.18 with stable NIM and credit; falsification cannot be specified responsibly until the source is available.
| Company | FY1 revision | FY2 mechanism | Thesis-pillar change | Business / estimate / stock delta |
|---|---|---|---|---|
| NVS | Slightly up | Priority brands less Entresto erosion and launch spend | Demand up; margin/cash mixed | + / + / + |
| SCHW | Modestly up | Asset flows × cash monetization, less sorting | Growth up; funding unresolved | + / + / - |
| DHR | Slightly up | Bioprocess order conversion and incremental margin | Orders up; timing down | Mixed / + / sharply - |
| MRSH | 1%–2% up | Organic growth plus acquisition/capital deployment | No structural change | + / + / + |
| MMM | About 3% up | Organic growth and restructuring, less legal cash | Demand/margin up | + / + / + |
| NOC | Reported up; operating flat/down | Program margin and cash milestones | Demand up; execution down | - / low-quality + / - |
| GM | 3%–4% up | Price/mix and lower EV drag, less tariffs | Margin/cash up | + / + / + |
| MSCI | Flat | Current net sales feed future subscriptions | Bookings down | - / flat / sharply - |
| DHI | Slightly up | Closings less incentive-driven margin | Volume up; margin down | Mixed / + / + |
| HAL | Flat/slightly up | International incrementals and FCF | Demand up; EPS flat | Mixed / flat / - |
| KEY | Slightly up | NIM less credit normalization | NIM up; credit down | Mixed / + / - |
| SYF | Up, less than headline | Purchase growth and NIM less losses/reserves | Core credit up; quality mixed | + / + / - |
| EFX | Flat/slightly up | Workforce margin plus realized AI savings | Core margin down | Mixed / + / sharply - |
| GPC | Flat | Industrial growth offsets auto softness | Mix shifts toward Industrial | Mixed / flat / + |
| ALLY | Flat | NIM/credit less provision and funding | Credit up; deposits down | Mixed / flat / + |
| HAS | Up | Magic growth plus Consumer recovery | Digital up; concentration up | + / + / + |
| VICR | Operating up; EPS beat normalized down | Backlog conversion versus capacity risk | Demand/margin up; quality weak | + / low-quality + / + |
| VMI | Up | Utility/grid demand less ag weakness | Infrastructure up | + / + / + |
| AUB | Slightly up | Organic NIM and synergies after accretion fades | Funding down | Mixed / + / - |
| UCB | Down on adjusted basis | Deposit-funded growth and post-Navitas earnings | Core earnings/funding down | - / - / - |
| OFG | Not verifiable | Source required | Unknown | Unknown / unknown / flat indication |
The complete release analysis and expectation stacks are preserved in [[EarningsBrief/EarningsBrief_2026-07-20_PM]]. The table below carries every name into the AM decision window, adds the overnight stock delta, and states the remaining transcript-dependent work. No complete call transcript was available in the deterministic AM evidence bundle.
| Company | Prior print versus bar | Release-only read and FY1/FY2 bridge | Overnight stock delta | Call status / decisive questions | Action and falsification |
|---|---|---|---|---|---|
| [[Steel Dynamics | STLD]] | EPS $3.69 vs $3.66 Street and $3.51–$3.55 guide; revenue $6.092B vs ~$5.53B | Steel spread/record shipments lift FY1; FY2 needs aluminum loss below $20M | -1.2% to $227.66 | Call today: aluminum ramp, $89/ton spread durability, fabrication backlog conversion |
| [[W. R. Berkley | WRB]] | Operating EPS $1.27 vs ~$1.09; combined ratio 90.0%, ex-cat 88.1% | Underwriting/NII lift estimates; slowing renewal rate makes FY2 selection-dependent | -3.6% to $70.10 | Partial public highlights only; require capital return and rate-versus-loss-cost detail |
| [[Crown Holdings | CCK]] | Adjusted EPS $2.49 vs $2.15 and $2.10–$2.20 guide; volume +5% | FY midpoint $8.40 and FCF ≥$900M support a true raise; FY2 depends on volume/margin | +2.6% to $117.50 | Call today: pass-through versus price/mix, Latin America, FCF sensitivity |
| [[AGNC Investment | AGNC]] | Net spread/dollar-roll $0.40 vs $0.38; tangible book $8.58 | Dividend currently covered; FY2 valuation depends on book/spread, not EPS alone | +1.2% to $11.05 | Call today: CPR miss, spread sensitivity, equity issuance above book |
| [[Wintrust Financial | WTFC]] | EPS $3.30 vs $3.15; revenue $738.6M vs ~$735M; NIM -4 bp | Asset growth lifts FY1; FY2 requires deposit-funded growth and stable NIM | -3.5% to $158.00 | Call today: deposit beta, loan verticals, expense normalization |
| [[Zions Bancorporation | ZION]] | $3.05 headline; ~$1.74 core vs $1.57 after Visa/SBIC gains | Core NII/fees improve; transaction gains do not recur | -5.4% to $68.00 | Partial public highlights; validate campaign deposits and buyback capital floor |
| [[BOK Financial | BOKF]] | $2.92 headline; ~$2.59 core vs ~$2.56 | Loans/deposits strong, fee weakness leaves FY1 near bar | Flat at $140.47 | Call today: NIM, fee pipeline, capital return |
| [[ServisFirst Bancshares | SFBS]] | EPS $1.57 in line; normalized NIM ~3.58% after recovery | FY1 benefits from repricing; FY2 constrained if loans keep outrunning deposits | -0.2% to $85.40 | Partial highlights; require deposit plan and CRE concentration detail |
| [[Calix | CALX]] | EPS $0.47 vs ~$0.41; Q3 GM midpoint ~280 bp below Q2 | Revenue/RPO support demand, but ~$8.5M quarterly gross-profit headwind cuts FY1/FY2 | -14.2% to $32.92 | Call today: memory duration, surcharge recovery, Calix One attach |
| [[Monarch Casino & Resort | MCRI]] | EPS $1.78 vs $1.75; revenue in line; EBITDA margin -30 bp | EPS rises faster than operations; FY2 needs margin ≥38% | Public quote blocked | No public call found; require property volume/price and EPS-to-EBITDA bridge |
| Company | Public EPS point | Decisive metric / non-consensus hurdle |
|---|---|---|
| [[Interactive Brokers | IBKR]] | $0.63 |
| [[Chubb | CB]] | $6.63 |
| [[Capital One | COF]] | $4.85 |
| [[EQT]] | $0.41 | Realized gas price/hedges, production, unit cost, FCF and debt reduction |
| [[East West Bancorp | EWBC]] | $2.61 |
| [[Annaly Capital Management | NLY]] | $0.75 |
| [[Webster Financial | WBS]] | $1.61 |
| [[Western Alliance Bancorporation | WAL]] | $2.33 |
| [[Range Resources | RRC]] | $0.52 |
| [[Bank OZK | OZK]] | $1.46 |
| [[Weatherford International | WFRD]] | $0.92 |
| [[Pegasystems | PEGA]] | $0.23 |
| [[Alaska Air Group | ALK]] | -$0.97 |
| Company | Public EPS point | Decisive metric / hurdle |
|---|---|---|
| [[AT&T | T]] | $0.59 |
| [[CME Group | CME]] | $2.91 |
| [[GE Vernova | GEV]] | $3.19 |
| [[Moody's | MCO]] | $4.24 |
| [[Northern Trust | NTRS]] | $2.71 |
| [[Philip Morris International | PM]] | $2.02 |
| [[PulteGroup | PHM]] | $2.36 |
| [[TE Connectivity | TEL]] | $2.84 |
| [[Teledyne Technologies | TDY]] | $5.79 |
| [[Westinghouse Air Brake Technologies | WAB]] | $2.60 |
No covered ticker had a pre-existing live TIF Ledger threshold, and no prior tracked catalyst arrived. Therefore the Analytical Ledger was not changed. The cross-company observations above are hypotheses from one session, not validated reusable signals; the Signal Library was not changed.
The PM workflow must revisit all 21 BMO companies after complete transcripts or attributable Q&A become available, with priority on DHR, MSCI, EFX, NOC, UCB, SCHW, MMM, GM, VICR, and NVS. It must also close today’s scheduled calls for STLD, CCK, AGNC, WTFC, BOKF, and CALX; retain partial status for WRB, ZION, and SFBS until a complete transcript is available; and continue to mark MCRI unavailable if no public call exists. For each, record whether management answered the decisive question, the evidence behind the answer, credibility change, and any new FY1/FY2 revision.
Primary or company-filed releases: Novartis Q2 release; Charles Schwab public FactSet report; Danaher SEC exhibit; Marsh McLennan SEC exhibit; 3M SEC exhibit; Northrop Grumman SEC exhibit; GM SEC exhibit; MSCI SEC exhibit; D.R. Horton public release; Halliburton SEC exhibit; KeyCorp SEC exhibit; Synchrony SEC exhibit; Equifax SEC exhibit; Genuine Parts SEC exhibit; Ally SEC exhibit; Hasbro SEC exhibit; Vicor SEC exhibit; Valmont SEC exhibit; Atlantic Union SEC exhibit; United Community Banks SEC exhibit.
Calendar and expectation cross-check: Kiplinger July 20–24 earnings calendar, updated 2026-07-17; Nasdaq earnings calendar. Prior-evening source set: [[EarningsBrief/EarningsBrief_2026-07-20_PM]]. Indicative quotes: public Yahoo Finance chart feed sampled 2026-07-21 at approximately 08:09 ET. Deterministic evidence bundle: /Users/max/morningsignal-research/state/earnings/earnings_context_2026-07-21_AM.json.
(source: EarningsBrief-AM, 2026-07-21) #sellside